Cetrorelix

證據等級: L5

預測適應症: 10 個

Cetrorelix: From Controlled Ovarian Stimulation to Hypertrichosis

One-Sentence Summary

Cetrorelix is a synthetic GnRH (gonadotropin-releasing hormone) antagonist, approved internationally for preventing premature LH surges during controlled ovarian stimulation in assisted reproductive technology (IVF/ART). The TxGNN model's top-ranked prediction is Hypertrichosis, with a prediction score of 99.98%; however, no clinical trials and no supporting literature exist for this indication, and the mechanistic rationale is weak. Among all 10 predicted indications, Central Precocious Puberty (CPP) at rank 10 is the most pharmacologically rational target based on cetrorelix's core GnRH antagonist mechanism.

Quick Overview

Item	Content
Original Indication	Controlled ovarian stimulation (prevention of premature LH surge in ART/IVF)
Predicted New Indication (Rank 1)	Hypertrichosis
TxGNN Prediction Score	99.98%
Evidence Level	L5
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological literature, cetrorelix is a synthetic decapeptide GnRH antagonist that competitively and reversibly blocks pituitary GnRH receptors, thereby suppressing LH and FSH secretion and reducing downstream gonadal steroid production. This mechanism is the basis for its use in controlled ovarian stimulation, where it prevents premature ovulation by blocking the endogenous LH surge.

The TxGNN model's top prediction — hypertrichosis — presents a meaningful mechanistic disconnect that warrants critical scrutiny. Hypertrichosis refers to excessive hair growth that is not androgen-dependent (in contrast to hirsutism, which is androgen-driven and where GnRH antagonism could theoretically reduce androgen levels). Most forms of hypertrichosis arise from genetic factors, medications (e.g., cyclosporine, minoxidil), or metabolic conditions entirely unrelated to the hypothalamic-pituitary-gonadal (HPG) axis. The network proximity of "hair-related disease" nodes in the TxGNN knowledge graph is the most plausible explanation for this high-scoring but mechanistically implausible prediction. The same reasoning applies to ranks 2 (Ambras type hypertrichosis universalis congenita — TRPS1 gene locus defect), 5 (isolated genetic hair shaft abnormality — KRT/LPAR6 structural mutations), and 7 (familial isolated trichomegaly), all of which are structural genetic disorders beyond the reach of hormonal modulation.

Among the full set of 10 predictions, Central Precocious Puberty (CPP, rank 10, L4) represents the strongest pharmacological case for cetrorelix repurposing. CPP is driven by premature activation of the GnRH pulse generator; cetrorelix's direct competitive blockade of pituitary GnRH receptors is precisely the mechanism needed to arrest HPG axis activation — the same principle that underlies FDA-approved GnRH agonist therapy (leuprolide) for CPP, with GnRH antagonists potentially offering the advantage of no initial hormonal flare. Aromatase Excess Syndrome (rank 9) presents an indirect but mechanistically coherent pathway: GnRH antagonism → LH/FSH suppression → reduced gonadal androgen substrate → reduced aromatase-driven estrogen overproduction, though this is a second-line mechanism compared to direct aromatase inhibitors.

Clinical Trial Evidence

Currently no related clinical trials registered for cetrorelix in hypertrichosis.

Literature Evidence

Currently no related literature available for cetrorelix in hypertrichosis.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top TxGNN prediction (hypertrichosis, L5) lacks mechanistic plausibility and any supporting clinical or preclinical evidence — it most likely reflects knowledge graph topology noise rather than a genuine drug-disease relationship. Across all 10 predicted indications, only Central Precocious Puberty (rank 10) achieves L4 evidence based on pharmacological class-level inference, and all predictions are classified as Hold or Research Question at this stage. Cetrorelix is also not currently marketed in Saudi Arabia, making regulatory pathway planning a prerequisite for any further development.

To proceed, the following is needed:

For CPP (most rational target): Systematic review of GnRH antagonist class data in pediatric CPP (degarelix, elagolix, relugolix Phase 1/2 studies) to assess class-effect extrapolation to cetrorelix; cetrorelix-specific PK/PD data relevant to pediatric dosing
MOA documentation: Retrieve full mechanism of action from DrugBank (DB00050) to complete mechanistic gap analysis and support or refute remaining predictions
Safety package: Obtain full package insert (key warnings, contraindications, pregnancy/lactation data, injection-site reactions) — currently classified as a Blocking data gap
Drug interaction profile: DDI search returned no results; a structured literature review of cetrorelix interactions with common ART and endocrine medications is required
Saudi Arabia regulatory pathway: Assess SFDA approval pathway for the GnRH antagonist drug class, especially for any potential pediatric (CPP) indication
Prediction triage: Formally deprioritize ranks 1–7 (hair/structural/non-HPG disease predictions) and focus any additional evidence collection on ranks 9 (Aromatase Excess Syndrome) and 10 (CPP)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.